Venus Pharma GmbH

Meropenem injectable formulations, developed under stringent International regulatory standards. Our flexible manufacturing capabilities allow us to cater to partner-specific requirements across global markets — whether for direct product supply or as a trusted third-party / contract manufacturing partner....

ENOXAPARIN PFS 100MG/ML

Dosage Strengths Available: 150 mg/15 ml, 450 mg/45 ml
Dosage Form: Ready-to-infuse vials·  Packaging: Single-use vial

Packing Options: Glass vials with flip-off seals and tear-off aluminum caps, available in single vial mono, or 10's vials pack

Customizat...

Cisplatin is a cytotoxic platinum-based compound that exerts its antineoplastic effect by crosslinking DNA, thereby inhibiting DNA replication and transcription in rapidly dividing cells. This DNA damage activates repair pathways and ultimately induces apoptosis if repair fails. Only the cis-isomer is...

Pack Strengths Available: 20 mg/0.5 ml, 20 mg/1 mL, 80mg/ 2ml,  80 mg/4 ml, 120 mg/ 3 ml and 160 mg/8 mL in single dose vials.
Dosage Form: Injectable solution for Intravenous Use (vial)

Packing Options: Glass vials with flip-off seals and tear-off aluminum caps, av...

Pack Strengths Available: Each concentrate vial contains docetaxel trihydrate equivalent to the labeled dose Strengths: 20 mg/0.5mL, 80 mg/2 mL, 120 mg/3mL,

Dosage Form: Injectable solution for Intravenous Use (vial)

Packing Options: Glass vials with flip-off seal...

Product Highlights:

Strengths Available: 10 mg/5 mL, 50 mg/25 mL, 200 mg/100 ml

Dosage Form: Solution for intravenous infusion (vial)

Packing Options: Glass vials with flip-off seals and tear-off aluminum caps, available in single vial mo...

Pack Strengths Available: 10 mg/ 5 ml , 50mg/25mL , 100 mg/ 50 ml and  200mg/100mL

Dosage Form: Injectable solution for Intravenous Use (vial)

Packing Options: Glass vials with flip-off seals and tear-off aluminum caps, available in single vial mono, com...

Etoposide Injection USP) is a semisynthetic derivative of podophyllotoxin used as an antineoplastic agent. It interferes with DNA synthesis by inhibiting topoisomerase II and is active in the late S and early G2 phases of the cell cycle. Supplied as a clear solution for intravenous infusion.

...

Fluorouracil Solution for Injection is an antineoplastic antimetabolite that interferes with DNA synthesis by inhibiting thymidylate synthase. It is used in a wide range of solid tumors, including colorectal, breast, gastric, pancreatic, and head & neck cancers.

Pack Strengths Available: 2...

Bendamustine Hydrochloride for Injection is a cytotoxic alkylating agent that causes DNA crosslinking, leading to cell death. It is used in the treatment of hematologic malignancies including chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (NHL) refractory to rituximab.

Pa...

Bleomycin for Injection is a cytotoxic glycopeptide antibiotic that causes DNA strand scission, leading to inhibition of cell replication and tumor cell death. It is used in a variety of malignancies, often in combination with other chemotherapeutic agents or radiation.

Pack Strengths Availabl...

“At Venus, we believe in science with conscience. Joining the UN Global Compact is a natural extension of our values—where access, ethics, and excellence intersect. This move not only amplifies our global credibility but also places us on the frontlines of change, where innovation must meet responsibility. We see this as a deep commitment to our global partners, to every healthcare system we serve, and to the planet we all share.”
— Ms. Aditi K. Chaudhary, President International Business, Venus Remedies Limited.

Venus Remedies and West Pharmaceutical Packaging @westatwork Kriti Kotian, Marketing Specialist at West Pharmaceutical Packaging India

Venus Remedies is proud to join United Nations Global Compact. Our commitment to the United Nations Global Compact is to embed #TenPrinciples on human rights, labour, environment, and anti-corruption into all our business operations. We look forward to driving meaningful impact through our dedication to global sustainability!
United Nations Global Compact

Join Venus Remedies and Venus Pharma GmbH at CPhI Milan 2024, from October 8th to 10th, in Hall 14, Meeting Rooms G52 & G54.

We're glad to announce the renewal of our GMP certification from Ukraine’s SMDC for our manufacturing facility. Covering cephalosporin, carbapenem, and oncology injectables, this certification strengthens our position in Ukraine and other 32 PIC/S countries. It reinforces our commitment to global quality standards and supports growth across the Asia-CIS region. With rising demand for generics and oncology care, we’re set to expand our reach and deliver high-quality therapies to more patients worldwide.

Venus Remedies Global Presence -96+ countries

We are proud to share that Venus Remedies Limited has officially joined the UN Global Compact—the world’s largest corporate sustainability initiative dedicated to upholding the principles of Human Rights, Labor, Environment, and Anti-Corruption.

Venus Remedies: A Global Pharma Force with Presence in 100 Countries and 800+ Marketing Authorizations

Venus Remedies’ novel polymyxin B formulation, VRP-034, has been granted QIDP status by the US FDA—a major breakthrough in combating antimicrobial resistance. Developed with our proprietary Renal Guard technology, VRP-034 reduces nephrotoxicity by up to 70% while maintaining efficacy against drug-resistant infections.

Venus Pharma GmbH is committed to the fight against cancer through itsadvanced range of Anticancer Injectables. Our products are designed to provide effective treatment options that address the unique needsof cancer patients. With a focus on precision, safety, and innovation, our injectables are developed using state-of-the-art technologies and rigorous quality standards. We aim to enhance patient outcomes and improve quality of life through therapies that target cancer at its core while minimizing adverse effects.

Pharma major Venus Remedies Limited has recently made significant progress in its global expansion by obtaining marketing approvals (MAs) for a wide range of drugs in different countries. We’re excited to share that Carboplatin and Carbol have been approved in Morocco, along with Bortezomib, Gemcitabine, Cefepime, and Oxaliplatin in the Philippines. In addition, we have received approvals for Meropenem in Hong Kong, Ceftriaxone in Mauritania, Methotrexate in Saudi Arabia, Imipenem/Cilastatin in Slovenia, Docetaxel in Portugal, and Ronem in El Salvador.

Venus Meropenem is revolutionizing the fight against serious bacterial infections. With its broad-spectrum action, it effectively targets conditions like pneumonia and urinary tract infections, providing healthcare professionals with a reliable solution. This innovative antibiotic exemplifies the advancements in medical treatment, ensuring better outcomes for patients facing complex infections.

Venus Remedies is thrilled to announce a major achievement: our pre-filled syringe (PFS) manufacturing unit in Baddi has been awarded the prestigious PIC/S GMP certification by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA). This is the first time our PFS facility has received accreditation under the Pharmaceutical Inspection Co-operation Scheme (PIC/S), marking an important step in our journey to bring world-class healthcare solutions to new markets.

Venus Remedies Limited is delighted to announce the successful registration of our Unit-2 in Baddi and Venus Pharma GmbH from Kuwait, alongside obtaining Marketing Authorizations (MAs) for Carboplatin 450 MG/45 ML. These achievements mark significant milestones in our ongoing commitment to expanding our global footprint and enhancing our pharmaceutical capabilities.

Venus Remedies is thrilled to announce a significant achievement in its ongoing mission to enhance cancer care with innovative solutions. The company's German subsidiary, Venus Pharma GmbH, has secured market authorization in the United Kingdom for Bleomycin 15,000 IU Powder for Solution for Injection/Infusion, marking a remarkable milestone for the organization.

Venus Remedies Featured in The Week for Groundbreaking Organ-on-a-Chip ResearchWe are proud to share that The Week has published an exclusive feature on Organ-on-a-Chip (OoAC) technology, incorporating valuable insights from Mr. Saransh Chaudhary, President – Global Critical Care, Venus Remedies Ltd., and CEO, Venus Medicine Research Centre (VMRC).https://www.theweek.in/news/health/2025/03/19/what-is-organ-on-a-chip-ooac-technology-new-method-to-aid-in-drug-testing-development.html

Venus Remedies has taken a significant step in combating Antimicrobial Resistance (AMR) by securing exclusive licensing rights for MET-X, an innovative anti-bacterial drug from UK-based Infex Therapeutics. This landmark partnership will enable Venus Remedies to develop, gain regulatory approvals, and commercialize MET-X in India, reinforcing its commitment to tackling drug-resistant infections.

Join us as Mr. Harmit Singh shares insights into his role at Venus Pharma GmbH and discusses the unique opportunities and challenges in the global markets he oversees. From representing Venus at CPHI Milan to achieving goals under the Passion Premier League, Mr. Singh provides a personal and professional perspective on the journey so far and strategies for future growth. Don’t miss his message to our audience and his thoughts on the exciting opportunities ahead for Venus Remedies.   https://www.youtube.com/watch?v=7GGZdKyAjpg&t=67s                             

Venus Remedies Limited, a global leader in the pharmaceutical industry, has achieved significant milestones by securing two prestigious tenders from globally renowned organizations—UNICEF and the Pan American Health Organization (PAHO). These wins mark a pivotal moment in the company's journey towards enhancing healthcare access and outcomes worldwide.

What an incredible final day at CPhI 2024! Venus Remedies wrapped up this amazing event with innovative showcases and powerful conversations with industry leaders. Thank you to everyone who joined us on this journey! Swipe to catch day 3 highlights!

Pharma major Venus Remedies on Tuesday said it has secured renewal of European Good Manufacturing Practices (EU-GMP) certification by Infarmed, the National Authority of Medicines and Health Products in Portugal. This renewal is applicable to the company's manufacturing facility for Cephalosporin, Carbapenem, and Oncology (Liquid and Lyophilized Injectable) formulations, a statement said.

Our efforts are well recognitioned by global regulatory authorities.Venus's passion for quality is reflected in its ability to align its organization-wide operations to global standards enabling it to secure global and national endorsements – its manufacturing facilities have thus far obtained more than 20 gmp approvals.

Venus' Product List for CPHI 2025